secwatch.observer — SEC 8-K summary
======================================

Issuer:     LifeStance Health Group, Inc. (LFST)
CIK:        0001845257
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0000950170-22-008508
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LifeStance Q1 rev +42% to $203.1M, net loss $62.3M on stock comp; reaffirms FY guidance
--------------------------------------------------------------------------------

- Revenue $203.1M (+42% YoY); net loss $62.3M (vs. $8.7M loss) driven by $59.9M stock-based comp.
- Adjusted EBITDA flat at $12.5M; Center Margin $54.2M (26.7% of rev, down from 30.7%).
- Total clinicians 4,989 (+51% YoY), net add of 199 in Q1; two acquisitions and 41 de novo centers.
- New $350M credit facility: $200M term loan, $100M delayed draw, $50M revolver; matures 2027-2028.
- Q2 2022 guidance: rev $209-214M, Center Margin $57-61M, Adj. EBITDA $12-15M; full-year reaffirmed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845257/000095017022008508/0000950170-22-008508-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845257/000095017022008508/lfst-20220504.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-008508

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer